Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
Lenalidomide (Revlimid)
Cat No.
CEI-0176
Description
Lenalidomide (Revlimid, CC-5013) can inhibit TNF-alpha secretion with IC50 of 13 nM.
Alias
CC-5013
CAS No.
191732-72-6
Molecular Weight
259.26
Purity
>99%
Storage
2 years at -20 centigrade
Synonyms
CC-5013
Targets
TNF-alpha
Molecular Formula
C13H13N3O3
Chemical Name
3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
Solubility
DSMO 52 mg/mL Water
In vitro
Lenalidomide strongly induces IL-2 and sIL-2R production. Lenalidomide-induced tyrosine phosphorylation of CD28 on T cells is followed by a down-stream activation of NF-kappaB. Lenalidomide prevents induction of defects by down-regulating tumor cell inhibitory molecule expression. Lenalidomide prevents induction of tumor-induced T cell lytic synapse dysfunction. Lenalidomide treatment prevents tumor-induced immune suppression in FL, DLBCL, HL, MM, SCC, and OC and down-regulates immunosuppressive ligand expression on all tumor cells examined.
In vivo
enalidomide significantly decreases the percentage of vascularized area from 5.16% (control group) to 2.58% (50 mg/kg). Lenalidomide significantly reduces the calculated total MVL from 21.07 (control) to 8.11 (50 mg/kg).
Download
Download Datasheet